Table 3.

Multivariate Cox proportional hazards regression analyses focusing on the MRD2nd

VariablesCIRRFSOS
HRLowerUpperPHRLowerUpperPHRLowerUpperP
Age* 0.995 0.984 1.007 .425 0.997 0.986 1.007 .561 1.012 1.000 1.024 .051 
WBC counts,* ×103/μL 1.004 1.001 1.007 .004 1.003 1.001 1.006 .011 1.003 1.000 1.006 .044 
ELN risk stratification   
 Intermediate vs favorable 1.990 1.322 2.995 .001 2.034 1.388 2.980 <.001 2.478 1.603 3.831 <.001 
 Adverse vs favorable 2.361 1.477 3.773 <.001 2.416 1.564 3.734 <.001 2.712 1.676 4.387 <.001 
Number of induction chemotherapy cycles 1.500 1.002 2.244 .049 1.497 1.032 2.172 .034 1.465 0.984 2.185 .060 
HSCT at CR1 0.202 0.116 0.53 <.001 0.286 0.180 0.455 <.001 0.578 0.362 0.922 .021 
MRD2nd§ 2.206 1.525 3.190 <.001 2.142 1.520 3.018 <.001 1.649 1.133 2.399 .009 
VariablesCIRRFSOS
HRLowerUpperPHRLowerUpperPHRLowerUpperP
Age* 0.995 0.984 1.007 .425 0.997 0.986 1.007 .561 1.012 1.000 1.024 .051 
WBC counts,* ×103/μL 1.004 1.001 1.007 .004 1.003 1.001 1.006 .011 1.003 1.000 1.006 .044 
ELN risk stratification   
 Intermediate vs favorable 1.990 1.322 2.995 .001 2.034 1.388 2.980 <.001 2.478 1.603 3.831 <.001 
 Adverse vs favorable 2.361 1.477 3.773 <.001 2.416 1.564 3.734 <.001 2.712 1.676 4.387 <.001 
Number of induction chemotherapy cycles 1.500 1.002 2.244 .049 1.497 1.032 2.172 .034 1.465 0.984 2.185 .060 
HSCT at CR1 0.202 0.116 0.53 <.001 0.286 0.180 0.455 <.001 0.578 0.362 0.922 .021 
MRD2nd§ 2.206 1.525 3.190 <.001 2.142 1.520 3.018 <.001 1.649 1.133 2.399 .009 
*

Continuous variables.

Two cycles vs 1 cycle.

HSCT at CR1 vs HSCT at other disease status or without HSCT.

§

MRD positivity vs negativity at the second time point. The MRD positivity and negativity are evaluated after excluding DTA mutations.

Close Modal

or Create an Account

Close Modal
Close Modal